Samantha R Scott1,2, Alison G O'Daffer1, Miranda C Bradford3, Kaitlyn Fladeboe1, Nancy Lau1, Angela Steineck1,4,5, Mallory Taylor1,4,5, Joyce P Yi-Frazier1, Abby R Rosenberg6,7,8. 1. Palliative Care & Resilience Lab, Seattle Children's Research Institute, Seattle, WA, USA. 2. Department of Psychology, University of Denver, Denver, CO, USA. 3. Children's Core for Biomedical Statistics, Seattle Children's Research Institute, Seattle, WA, USA. 4. University of Washington School of Medicine, Seattle, WA, USA. 5. Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 6. Palliative Care & Resilience Lab, Seattle Children's Research Institute, Seattle, WA, USA. Abby.Rosenberg@seattlechildrens.org. 7. University of Washington School of Medicine, Seattle, WA, USA. Abby.Rosenberg@seattlechildrens.org. 8. Fred Hutchinson Cancer Research Center, Seattle, WA, USA. Abby.Rosenberg@seattlechildrens.org.
Abstract
OBJECTIVE: In adolescents and young adults (AYAs) with cancer, we examined (1) the distribution and type of traumatic events (TEs) experienced prior to baseline assessment and (2) how a resilience intervention, Promoting Resilience in Stress Management (PRISM), impacted changes in patient-reported outcomes (PROs) for AYAs with and without TEs. METHODS: AYAs (12-25 years) within 1-10 weeks of diagnosis of new malignancy or ever diagnosed with advanced cancer were enrolled and randomly assigned to usual care (UC) with or without PRISM. To assess TEs, we screened medical records for traditionally defined adverse childhood experiences (ACEs) and medical traumatic events. Age-validated PROs assessed resilience, benefit-finding, hope, generic health-related quality of life (QoL), cancer-specific QoL, depression, and anxiety at enrollment and 6 months later. We calculated effect sizes (Cohen's d) for PRISM vs. UC effect on PRO score change at 6 months for 1+ TEs and 0 TE groups. RESULTS: Ninety-two AYAs enrolled and completed baseline surveys (44-UC, 48-PRISM; N = 74 at 6 months, 38-UC, 36-PRISM); 60% experienced 1+ TEs. PROs at baseline were similar across groups. PRISM's effect on score change was greater (Cohen's d ≥ 0.5) for the 1+ TE group on domains of benefit-finding and hope; and similar (d < 0.5) on domains of resilience, depression, anxiety, and both generic and cancer-specific QoL. CONCLUSIONS: In AYAs with cancer, TEs occurred at similar rates as the general population. PRISM may be particularly helpful for improving benefit-finding and hope for those who have experienced TEs.
OBJECTIVE: In adolescents and young adults (AYAs) with cancer, we examined (1) the distribution and type of traumatic events (TEs) experienced prior to baseline assessment and (2) how a resilience intervention, Promoting Resilience in Stress Management (PRISM), impacted changes in patient-reported outcomes (PROs) for AYAs with and without TEs. METHODS: AYAs (12-25 years) within 1-10 weeks of diagnosis of new malignancy or ever diagnosed with advanced cancer were enrolled and randomly assigned to usual care (UC) with or without PRISM. To assess TEs, we screened medical records for traditionally defined adverse childhood experiences (ACEs) and medical traumatic events. Age-validated PROs assessed resilience, benefit-finding, hope, generic health-related quality of life (QoL), cancer-specific QoL, depression, and anxiety at enrollment and 6 months later. We calculated effect sizes (Cohen's d) for PRISM vs. UC effect on PRO score change at 6 months for 1+ TEs and 0 TE groups. RESULTS: Ninety-two AYAs enrolled and completed baseline surveys (44-UC, 48-PRISM; N = 74 at 6 months, 38-UC, 36-PRISM); 60% experienced 1+ TEs. PROs at baseline were similar across groups. PRISM's effect on score change was greater (Cohen's d ≥ 0.5) for the 1+ TE group on domains of benefit-finding and hope; and similar (d < 0.5) on domains of resilience, depression, anxiety, and both generic and cancer-specific QoL. CONCLUSIONS: In AYAs with cancer, TEs occurred at similar rates as the general population. PRISM may be particularly helpful for improving benefit-finding and hope for those who have experienced TEs.
Authors: Abby R Rosenberg; Joyce P Yi-Frazier; Claire Wharton; Karen Gordon; Barbara Jones Journal: J Adolesc Young Adult Oncol Date: 2014-12-01 Impact factor: 2.223
Authors: Abby R Rosenberg; Miranda C Bradford; Krysta S Barton; Nicole Etsekson; Elizabeth McCauley; J Randall Curtis; Joanne Wolfe; K Scott Baker; Joyce P Yi-Frazier Journal: Pediatr Blood Cancer Date: 2018-09-30 Impact factor: 3.167
Authors: Emalee G Flaherty; Richard Thompson; Alan J Litrownik; Adam J Zolotor; Howard Dubowitz; Desmond K Runyan; Diana J English; Mark D Everson Journal: Acad Pediatr Date: 2009 May-Jun Impact factor: 3.107
Authors: Abby R Rosenberg; Miranda C Bradford; Elizabeth McCauley; J Randall Curtis; Joanne Wolfe; K Scott Baker; Joyce P Yi-Frazier Journal: Cancer Date: 2018-09-19 Impact factor: 6.860
Authors: Tracie O Afifi; Derek Ford; Elizabeth T Gershoff; Melissa Merrick; Andrew Grogan-Kaylor; Katie A Ports; Harriet L MacMillan; George W Holden; Catherine A Taylor; Shawna J Lee; Robbyn Peters Bennett Journal: Child Abuse Negl Date: 2017-01-23
Authors: Abby R Rosenberg; Chuan Zhou; Miranda C Bradford; John M Salsman; Katie Sexton; Alison O'Daffer; Joyce P Yi-Frazier Journal: JAMA Netw Open Date: 2021-11-01